Associated Papers
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Activation of FGFR genes by genetic and epigenetic alterations in uterine leiomyomas.
Jokinen V et al.
Bjc Reports, 2025
Differential Expression of Small Non-Coding RNAs in Uterine Leiomyomas.
Chuang TD et al.
International Journal of Molecular Sciences, 2025
Detection of exon2-MED12 mutations in uterine leiomyomas from Syrian patients.
Albitar L et al.
Scientific Reports, 2025
Somatic MED12 Mutations in Myometrial Cells.
Li Y et al.
Cells, 2024
The Effect of Race/Ethnicity and MED12 Mutation on the Expression of Long Non-Coding RNAs in Uterine Leiomyoma and Myometrium.
Chuang TD et al.
International Journal of Molecular Sciences, 2024
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Differential Expression of MED12-Associated Coding RNA Transcripts in Uterine Leiomyomas.
Chuang TD et al.
International Journal of Molecular Sciences, 2023
MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K et al.
American Journal of Obstetrics and Gynecology, 2023
Prevalence and clinical significance of co-existing mutations in MED12 and FH in uterine fibroids of Australian women.
Jamaluddin MFB et al.
Frontiers in Reproductive Health, 2023
Further characterization of tryptophan metabolism and its dysregulation in fibroids.
Chuang TD et al.
F&s Science, 2022
Long Noncoding RNA MIAT Modulates the Extracellular Matrix Deposition in Leiomyomas by Sponging MiR-29 Family.
Chuang TD et al.
Endocrinology, 2021
Insights into the regulatory role and clinical relevance of mediator subunit, MED12, in human diseases.
Srivastava S et al.
Journal of Cellular Physiology, 2021
Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
Otsuji K et al.
British Journal of Cancer, 2021
The genomic mutation spectrums of breast fibroadenomas in Chinese population by whole exome sequencing analysis.
Xie SN et al.
Cancer Medicine, 2019
Recurrent MED12 exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults.
Pareja F et al.
Journal of Clinical Pathology, 2019
MED12 somatic mutations encompassing exon 2 associated with benign breast fibroadenomas and not breast carcinoma in Indian women.
Darooei M et al.
Journal of Cellular Biochemistry, 2019
Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas.
Park MJ et al.
The Journal of Clinical Endocrinology and Metabolism, 2018
Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.
Vaisitti T et al.
Cancer Research, 2018
Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer.
Rohan TE et al.
British Journal of Cancer, 2018
Clinical, pathologic, cytogenetic, and molecular profiling in self-identified black women with uterine leiomyomata.
Hayden MA et al.
Cancer Genetics, 2018
Proteomic Profiling of Human Uterine Fibroids Reveals Upregulation of the Extracellular Matrix Protein Periostin.
Jamaluddin MFB et al.
Endocrinology, 2018
Analysis of MED12 Mutation in Multiple Uterine Leiomyomas in South Korean patients.
Lee M et al.
International Journal of Medical Sciences, 2018
Expanded Somatic Mutation Spectrum of MED12 Gene in Uterine Leiomyomas of Saudi Arabian Women.
Ajabnoor GMA et al.
Frontiers in Genetics, 2018
Global metabolomic profiling of uterine leiomyomas.
Heinonen HR et al.
British Journal of Cancer, 2017
MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia.
Wu B et al.
British Journal of Haematology, 2017
Prevalence and clinical significance of mediator complex subunit 12 mutations in 362 Han Chinese samples with uterine leiomyoma.
Wu J et al.
Oncology Letters, 2017
Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N et al.
Molecular Cancer, 2017
Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
Nozad S et al.
Breast Cancer Research and Treatment, 2017
Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA et al.
Fertility and Sterility, 2017
MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
Laé M et al.
Oncotarget, 2016
MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
Kämpjärvi K et al.
British Journal of Cancer, 2016
Frequency of MED12 mutations in phyllodes tumors: Inverse correlation with histologic grade.
Yoon N et al.
Genes, Chromosomes & Cancer, 2016
MED12 exon 2 mutation as a highly sensitive and specific marker in distinguishing phyllodes tumours from other spindle neoplasms of the breast.
Lien HC et al.
Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, 2016
Mutational analysis of MED12 exon 2 in a spectrum of fibroepithelial tumours of the breast: implications for pathogenesis and histogenesis.
Lien HC et al.
Histopathology, 2016
The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.
Sadeghi S et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2016
MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.
Piscuoglio S et al.
Histopathology, 2015
MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.
Ng CC et al.
Journal of Clinical Pathology, 2015
Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing.
Mishima C et al.
Breast Cancer Research and Treatment, 2015
Frequent MED12 mutations in phyllodes tumours of the breast.
Yoshida M et al.
British Journal of Cancer, 2015
Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids.
Halder SK et al.
Molecular Genetics and Genomics : Mgg, 2015
Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
Cani AK et al.
Molecular Cancer Research : Mcr, 2015
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia.
Kämpjärvi K et al.
Oncotarget, 2015